Nissay Asset Management Corp Alkermes Plc. Transaction History

Nissay Asset Management Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $13,286 - $16,534	681 Added 4.78%	14,914 $291,000
Q2 2019 Aug 07, 2019	BUY	$21.47 - $37.33 $15,071 - $26,205	702 Added 5.19%	14,233 $321,000
Q1 2019 May 03, 2019	BUY	$28.4 - $36.49 $17,238 - $22,149	607 Added 4.7%	13,531 $494,000
Q4 2018 Feb 06, 2019	BUY	$27.94 - $44.61 $27,157 - $43,360	972 Added 8.13%	12,924 $381,000
Q3 2018 Oct 30, 2018	BUY	$38.6 - $46.12 $12,622 - $15,081	327 Added 2.81%	11,952 $507,000
Q2 2018 Aug 08, 2018	BUY	$40.56 - $51.36 $31,474 - $39,855	776 Added 7.15%	11,625 $478,000
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $10,507 - $13,182	196 Added 1.84%	10,849 $629,000
Q4 2017 Feb 14, 2018	BUY	$47.69 - $55.39 $508,041 - $590,069	10,653	10,653 $584,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.